Other news to note for March 3, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: 1st Biotherapeutics, Altimmune, Arcus, Ascletis, Astrazeneca, Basilea, Daiichi Sankyo, Dyadic, Dynavax, Evqlv, Generex, Glenmark, Hikma, Hypera, Immunoprecise Antibodies, Innovation, Nektar, Novavax, Pfizer, Pvp Biologics, Redhill, Sonoma, Sumitomo Dainippon, Taiho, Takeda, Twoxar, Vir, Wuxi.

Regulatory front for March 3, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: FDA, Yibin Lihao Bio-technical.

Financings for March 3, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Biolexis, Outlook Therapeutics.

Earnings for March 3, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Amicus Therapeutics.

Appointments and advancements for March 3, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Sumitomo Dainippon Pharma.

Clinical data for Feb. 25-March 2, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Apeiron Biologics.

Regulatory actions for Feb. 25-March 2, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Kyowa Kirin, Noxopharm, Shionogi, Takeda, Tessa, Ultragenyx.

No Comments